|
May 8, 2023
|
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
|
|
May 2, 2023
|
Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023
|
|
April 25, 2023
|
Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million
|
|
April 17, 2023
|
Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
|
|
April 6, 2023
|
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
|
|
April 5, 2023
|
Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
|
|
March 14, 2023
|
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
|
|
March 8, 2023
|
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
|
|
March 7, 2023
|
Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
|
|
February 7, 2023
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET
|